Bicara Therapeutics Inc. Common Stock Cash Flow-to-Debt Ratio
Bicara Therapeutics Inc. Common Stock cash flow-to-debt ratio. Bicara Therapeutics Inc. Common Stock (BCAX) has a Cash Flow-to-Debt Ratio of -1.02x as of June 2026, meaning its operating cash flow of $-44.21 Million could theoretically repay -1% of its total liabilities ($43.48 Million) in one year. See Bicara Therapeutics Inc. Common Stock (BCAX) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Bicara Therapeutics Inc. Common Stock (2022–2025)
Cash flow-to-debt ratio of Bicara Therapeutics Inc. Common Stock from 2022 to 2025. Historical debt coverage capacity for Bicara Therapeutics Inc. Common Stock across 4 annual periods. Also explore Bicara Therapeutics Inc. Common Stock (BCAX) equity growth momentum to track the company's year-over-year net asset growth rate.
Bicara Therapeutics Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2022–2025)
Bicara Therapeutics Inc. Common Stock cash flow-to-debt ratio by year from 2022 to 2025. Year-by-year debt coverage analysis for Bicara Therapeutics Inc. Common Stock. For the full cash flow conversion analysis, see cash efficiency ratio of Bicara Therapeutics Inc. Common Stock.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.62x | $-106.83 Million | $29.54 Million | ▼ -274.1% |
| 2024 | -0.97x | $-74.75 Million | $77.32 Million | ▲ +67.2% |
| 2023 | -2.95x | $-45.63 Million | $15.47 Million | ▼ -120.5% |
| 2022 | -1.34x | $-32.08 Million | $23.98 Million | — |